Neonatal administration of monosodium glutamate (MSG) to rodents results in severe damage to the arcuate nucleus of the hypothalamus (AN). MSG-induced AN damage produces profound alterations in hypothalamic neuro-transmitters and anterior pituitary function. Reproductive function is also severely compromised in both male and female MSG-treated rats. The present study investigated the developmental sequelae of MSG-induced alterations in hypothalamic monoamine metabolism as well as other aspects of MSG toxicity. Female rats given 4 mg/g of MSG on postnatal days 2 and 4 did not exhibit any significant alterations in hypothalamic monoamine metabolism on postnatal days 21 or 30, however, postpubertal MSG-treated females had significantly reduced levels of mediobasal hypothalamic (MBH) dopamine and DOPAC. In contrast, male MSG-treated rats had slight reductions in hypothalamic and MBH dopamine levels but these reductions were not statistically significant. Male MSG-treated rats did exhibit significant reductions in hypothalamic DOPAC on postnatal day 30 and MBH homovanillic acid (HVA) levels on day 100. Acetylcholine levels were also measured in the MBH and pituitary of adult male MSG-treated rats and found to be unaltered. The developmental profile of hypothalamic monoamines and their metabolites and MSG-induced alterations in dopamine and DOPAC levels in the MBH of female rats are discussed in relation to the neurochemical mechanisms involved in triggering puberty.

Keywords:
Monosodium glutamate, Hypothalamus, Developmental neurochemistry, Dopamine, Puberty
This content is only available via PDF.
© 1986 S. Karger AG, Basel
1986
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.